AI GRAND ROUNDS

Authors: GEMINI (RESIDENT), GROK (ATTENDING), KIMI (EXPERT) & ANUPAM SINGH MD (Human in loop)

Department of Medicine, Santosh Medical College.

Click here for App | Agentic Grand Rounds Index

Round 1

User:

STAGE 1: Initial Presentation & Baseline Workup

A 74-year-old man, a health-care worker and lifelong nonsmoker from a suburb of a North Indian metro with a background of hypertension and dyslipidemia, presents to the emergency department with dyspnea, proximal muscle weakness, and hypoxemia.

Timeline of the illness:
- 7 months before presentation: intermittent binocular diplopia developed. An ophthalmologist documented right-eye ptosis and fluctuating strabismus without a cranial nerve abnormality. Acetylcholine receptor antibodies were positive. CT chest showed a normal thymus. Pyridostigmine was started for presumed ocular myasthenia gravis.
- 5 months before presentation: diarrhea developed after starting pyridostigmine, which was stopped. Prednisone was started; the diarrhea resolved, but ocular symptoms persisted and the prednisone dose was increased gradually over 2 months.
- 3 months before presentation: ocular symptoms persisted despite the higher prednisone dose. White-cell count 8970/microliter, absolute lymphocyte count 580/microliter (reference 720-4100), platelet count 146,000/microliter. Mycophenolate mofetil was added.
- 2 months before presentation: ocular symptoms resolved, but leg swelling, weight gain, moon facies, and oral thrush developed. Prednisone was tapered.
- 5 weeks before presentation: a painful tongue lesion developed, limiting oral intake. Viscous-lidocaine mouthwash provided no relief.
- 3 weeks before presentation: two to three episodes of nonbloody, watery diarrhea per day began.
- 6 days before presentation: progressive proximal leg weakness made rising from a seated position difficult; dyspnea on exertion developed.

On presentation:
- Examination: temperature 37.2°C, BP 112/64, HR 111, RR 22, SpO2 87% on room air (rising to 98% on 5 L/min nasal cannula), BMI 24.5. Horizontal diplopia on sustained upward gaze, weakness on eye closure, 4/5 strength in elbow and hip flexion, 4/5 in shoulder abduction after 20 repetitions, hoarse voice, mild dysarthria, counted to 16 in one breath. Tongue: raised erythematous area on the dorsal aspect, ulcerated lateral lesions, and a white dorsal exudate. Mild ankle edema, no rash.
- Key labs: Hemoglobin 10.5 g/dL, hematocrit 31.5%, WBC 4520 (neutrophils 3860, lymphocytes 40, monocytes 140), platelets 129,000; AST 51, ALT 59, ALP 42, total bilirubin 0.5, albumin 2.5 g/dL. Arterial blood gas: pH 7.51, pCO2 29 mm Hg, pO2 81 mm Hg.
- CT chest (pulmonary-artery protocol): no pulmonary embolism; scattered mild interlobular septal thickening, bronchial-wall thickening, a 6-mm centrilobular nodule, bibasilar atelectasis with heterogeneity in the left lower lobe and a trace left effusion (findings possibly reflecting aspiration).
- Stool testing for C. difficile and Shiga toxins 1 and 2: negative.

Medications at admission: amlodipine, mycophenolate mofetil, omeprazole, prednisone, and prophylactic sulfamethoxazole-trimethoprim. Prior screening (3 months ago) for hepatitis B/C and an interferon-gamma release assay for tuberculosis were negative. He had spent the previous 4 weeks on a coastal holiday.

Resident:

Hello, Chief Resident here.

Key Findings: Profound lymphopenia (ALC 40/µL) secondary to prednisone and mycophenolate mofetil, painful ulcerative tongue lesions, chronic diarrhea, proximal weakness, hypoxemic respiratory distress, and CT evidence of subtle pulmonary infiltrates/aspiration.

Differential Diagnoses:
1. Disseminated/Multisystem Opportunistic Infection (e.g., CMV, PCP, Histoplasma, Strongyloides): 50% – Severe iatrogenic T-cell depletion strongly predisposes to disseminated viral, fungal, or parasitic pathogens explaining mucosal, GI, and respiratory features.
2. Infection-Triggered Myasthenic Crisis: 25% – Exacerbation of underlying AChR+ myasthenia gravis, precipitated by an occult or overt systemic infection.
3. Steroid Myopathy with Mucocutaneous/GI Opportunistic Infection: 15% – Weakness secondary to prolonged glucocorticoids, complicated by secondary enteritis/stomatitis.
4. Lymphoproliferative or Paraneoplastic Process: 10% – Occult malignancy or immunodeficiency-associated lymphoproliferative disease.

Recommended Prioritized Tests:
1. Serum CMV PCR and HIV 1/2 serology/viral load.
2. Biopsy/swab of tongue lesion for viral PCR (HSV, CMV) and fungal stains.
3. Bronchoscopy with BAL for PCP PCR, bacterial, AFB, and fungal cultures.
4. Stool microscopy/PCR for Strongyloides, Cryptosporidium, and Microsporidia.
5. Serum Beta-D-glucan and Histoplasma antigen testing.

Attending:

Hello Attending Consultant here

Critique: Solid prioritization of iatrogenic T-cell failure, but underweights endemic mycoses (coastal holiday + North India) and over-relies on BAL early; tongue biopsy first is higher-yield/lower-risk. Myasthenic crisis remains plausible but secondary until infection excluded. No mention of holding MMF or stress-dose steroids.

Top 3 DDx:
1. Disseminated histoplasmosis (mucosal ulcer + diarrhea + hypoxemia + lymphopenia)
2. CMV disease (colitis/pneumonitis/esophagitis) ± myasthenic exacerbation
3. PCP + steroid myopathy

Specific points:
1. Urgent tongue biopsy/scraping: GMS, PAS, HSV/CMV IHC/PCR, Histoplasma Ag.
2. Serum/urine Histoplasma Ag + β-D-glucan + cryptococcal Ag.
3. Plasma CMV PCR + quantitative HIV RNA (despite prior negatives).
4. Hold mycophenolate; continue TMP-SMX; consider empiric liposomal Ambisome if unstable.
5. NIF/VC q4h + ABG; prepare for BiPAP/ICU, not immediate bronchoscopy.
6. Stool Strongyloides PCR/serology + Cryptosporidium.
7. Repeat AChR Ab + consider IVIG only after infection screen.

Expert:

Hello, Expert Clinician here.

Best unifying diagnosis: Disseminated histoplasmosis in an iatrogenically immunosuppressed host (ALC 40/µL from prednisone + mycophenolate). It unifies the painful tongue ulcer, chronic watery diarrhea (GI involvement), hypoxemia with septal thickening/centrilobular nodule, cytopenias, and hypoalbuminemia. Endemic exposure (North India, coastal travel) fits.

Top differentials:
- CMV disease — colitis, pneumonitis, and mucosal ulcers fit perfectly; co-infection with histoplasmosis is possible. Must test in parallel.
- Strongyloides hyperinfection — coastal exposure + steroids; diarrhea and pulmonary infiltrates fit, but tongue ulcer does not.
- PCP — hypoxemia fits, but TMP-SMX prophylaxis and prominent mucosal/GI disease argue against.
- Myasthenic crisis vs steroid myopathy — explains weakness but is a contributor, not the unifier; infection likely the trigger.

Key pivot: The profound lymphopenia reframes this from "refractory myasthenia" to opportunistic infection; the tongue lesion is the accessible diagnostic window.

Next move: Urgent tongue biopsy (fungal stains, CMV/HSV IHC) plus serum/urine Histoplasma antigen and plasma CMV PCR; hold mycophenolate.

Teaching pearl: In combined immunosuppression, new mucosal ulcer + diarrhea + hypoxemia is disseminated infection until proven otherwise — biopsy the accessible lesion first.

Round 2

User:

STAGE 2: Progression in Hospital & Diagnostic Considerations

Over the next 3 days the patient's condition evolved. Treatment with mycophenolate mofetil was stopped, prednisone continued, and intravenous immune globulin was given daily for 3 days. Oral intake remained limited by tongue pain.

Hospital day 3 laboratory data:
- Hemoglobin 9.6 g/dL, hematocrit 27.3%, WBC 2110 (neutrophils 1890, lymphocytes 40, monocytes 70, eosinophils 0, basophils 0), platelet count 106,000.
- AST 116 U/L, ALT 118 U/L, ALP 54 U/L, total bilirubin 0.6, direct bilirubin 0.3, albumin 2.1 g/dL, total protein 5.8 g/dL.

Resident:

Hello, Chief Resident here.

Updated Key Findings: Rapidly progressive pancytopenia (WBC 2,110/µL, Hgb 9.6 g/dL, Plts 106,000/µL), new acute transaminitis (AST 116 U/L, ALT 118 U/L), persistent T-cell lymphopenia (ALC 40/µL), and non-responsive tongue ulcers following IVIG.

Differential Diagnoses:
1. Disseminated Histoplasmosis: 60% – Unifies the ulcerative mucosal lesions, GI involvement, pulmonary infiltrates, worsening cytopenias, and acute hepatic injury in a T-cell-depleted host.
2. Disseminated Cytomegalovirus (CMV) Disease: 25% – Can independently cause mucosal/GI ulceration, marrow suppression, hepatitis, and pneumonitis.
3. Infection-Induced Secondary HLH / MAS: 10% – Explains the accelerating cytopenias, transaminitis, and systemic collapse triggered by an occult opportunistic pathogen.
4. Disseminated Tuberculosis or Visceral Leishmaniasis: 5% – Important regional endemic considerations in North India presenting with reticuloendothelial involvement.

Recommended Prioritized Tests:
1. Urgent biopsy/scraping of the tongue lesion for fungal stains (GMS/PAS), HSV/CMV IHC, and cultures.
2. Urine and serum Histoplasma antigen testing.
3. Quantitative plasma CMV PCR.
4. HLH biomarkers: Serum ferritin, triglycerides, and fibrinogen levels.
5. Bone marrow aspirate and biopsy for histology, special stains, and cultures.

Attending:

Hello Attending Consultant here

Critique: Appropriate halt of MMF and recognition of progressive marrow/hepatic injury, but IVIG prematurely risks confounding without infection exclusion. Over-prioritizes BM biopsy; accessible tongue lesion remains highest-yield. Underweights empiric coverage amid rapid decline and ignores serial NIF/VC.

Top 3 DDx:
1. Disseminated histoplasmosis (ulcer + diarrhea + cytopenias + hepatitis + infiltrates)
2. CMV visceral disease ± secondary HLH
3. Mixed opportunistic infection (histo/CMV) driving marrow failure

Specific points:
1. Immediate tongue biopsy: GMS/PAS, CMV/HSV IHC, fungal culture.
2. Serum/urine Histoplasma Ag + β-D-glucan + plasma CMV PCR now.
3. Ferritin, trigs, fibrinogen, sIL-2R for HLH score.
4. Hold further IVIG; stress-dose steroids only if crisis confirmed.
5. Empiric liposomal amphotericin if unstable pending Ag.
6. Daily NIF/VC + ICU standby; defer BAL.
7. Strongyloides serology/PCR given steroids + travel.

Expert:

Hello, Expert Clinician here.

Best unifying diagnosis: Disseminated histoplasmosis with evolving secondary HLH. The new transaminitis, accelerating pancytopenia, and falling albumin reflect reticuloendothelial involvement and cytokine-driven marrow suppression — classic for disseminated histoplasmosis in a T-cell-depleted host. IVIG non-response argues against a purely autoimmune process.

Top differentials:
- CMV disease ± HLH — hepatitis, cytopenias, and mucosal ulcers fit; may co-exist with histoplasmosis. Test in parallel.
- Visceral leishmaniasis (kala-azar) — North India endemic; pancytopenia, hepatitis, and marrow involvement fit, but tongue ulcer and pulmonary findings are atypical.
- Disseminated TB — possible despite negative IGRA (anergic in lymphopenia); less likely given mucosal ulcer.
- Drug-induced marrow/hepatic injury — TMP-SMX or MMF, but tempo and systemic picture favor infection.

Key pivot: Failure to improve with IVIG plus new hepatitis/cytopenias confirms this is infection-driven, not autoimmune.

Next move: Tongue biopsy now (fungal stains, CMV IHC) + Histoplasma antigen + CMV PCR + ferritin/fibrinogen/triglycerides; start empiric liposomal amphotericin B if unstable.

Teaching pearl: Rising transaminases with falling cell lines in an immunosuppressed host signals disseminated fungal disease with HLH — don't wait for cultures to treat.

Round 3

User:

STAGE 3:

Clinical course: Intravenous ganciclovir and CMV immune globulin were started on hospital day 3. On day 14, after the CMV DNA level had fallen and clinical improvement was evident, therapy was transitioned to oral valganciclovir. Antiviral therapy was planned for at least 3 months with an undetectable CMV DNA goal, with surveillance for immune reconstitution inflammatory syndrome. The patient was discharged on day 20 to a rehabilitation facility; strength gradually improved.

Resident:

Hello, Chief Resident here.

Updated Key Findings: Diagnostic confirmation of severe, tissue-invasive CMV disease via massive viremia (CMV DNA 6,270,000 IU/mL) and tongue biopsy demonstrating viral cytopathic changes (owl-eye inclusions) with positive CMV IHC. Rapid clinical and hematologic response to ganciclovir confirms the primary etiology.

Final Diagnostic Probabilities:
1. Disseminated CMV Disease (Mucocutaneous, GI, Hepatic, Marrow, Pulmonary): 95% – Fully unifies the ulcerative tongue lesions, chronic diarrhea, pneumonitis, transaminitis, and pancytopenia driven by profound iatrogenic T-cell depletion (ALC 40/µL).
2. CMV-Precipitated Myasthenic Exacerbation / Steroid Myopathy: 5% – Weakness represented a secondary flare of underlying AChR+ myasthenia gravis triggered by severe systemic infection, now resolving following antiviral therapy and rehabilitation.

Next Steps & Management:
1. Continue oral valganciclovir for at least 3 months targeting sustained undetectable CMV DNA.
2. Monitor quantitative CMV PCR, CBC (for valganciclovir-induced neutropenia), and liver function tests biweekly.
3. Vigilance for Immune Reconstitution Inflammatory Syndrome (IRIS) during immunosuppressive taper.
4. Outpatient neurology follow-up to carefully titrate residual myasthenia gravis maintenance therapy.

Attending:

Hello Attending Consultant here

Critique: Correctly locks onto tissue-invasive CMV as the unifier and notes secondary MG contribution. However, under-emphasizes residual risk of co-infection (histoplasma/Strongyloides) given endemic exposure and incomplete workup; omits HLH labs and long-term immunosuppression strategy. IRIS surveillance is noted but lacks concrete triggers/monitoring.

Top 3 DDx:
1. Disseminated CMV (biopsy/viremia-proven; mucocutaneous/GI/hepatic/marrow)
2. CMV + occult endemic co-infection (histoplasma)
3. CMV-triggered myasthenic crisis + steroid myopathy

Specific points:
1. Complete pending Histoplasma Ag/β-D-glucan and Strongyloides serology before full recovery assumed.
2. Check ferritin/trigs/fibrinogen retrospectively for occult HLH.
3. Valganciclovir 900 mg BID → adjust for CrCl; weekly CMV PCR + ANC.
4. Hold all cell-cycle agents ≥3 mo; slow prednisone taper with NIF/VC monitoring.
5. Ophthalmology/ENT re-eval of residual ocular MG; defer further IVIG.
6. IRIS watch: fever/worsening infiltrates → low-dose steroids if needed.
7. Rehab + PT; reassess AChR titers only after viral clearance.

Expert:

Hello, Expert Clinician here.

Final unifying diagnosis: Disseminated CMV disease (mucocutaneous, GI, hepatic, marrow, pulmonary) in a profoundly T-cell-depleted host (ALC 40/µL from prednisone + mycophenolate), with secondary myasthenic exacerbation and steroid myopathy. Biopsy-proven tissue invasion plus massive viremia (6.27M IU/mL) and rapid ganciclovir response confirm this.

Why differentials fell away:
- Histoplasmosis — plausible clinically, but negative antigen testing and CMV-specific histopathology with treatment response exclude it as primary.
- Strongyloides/PCP — never confirmed; CMV explains all findings.
- Primary myasthenic crisis — weakness was real but infection-triggered; IVIG failure and antiviral success prove the driver.

Key pivot: The tongue biopsy — an accessible lesion yielding definitive histopathology — converted a broad opportunistic-infection differential into a single treatable diagnosis.

Next moves: Complete valganciclovir course to undetectable PCR; weekly CBC/CMV monitoring; slow steroid taper with respiratory surveillance; watch for IRIS during immune recovery.

Teaching pearl: In iatrogenic immunosuppression, biopsy the accessible lesion early — tissue diagnosis beats empiricism, and CMV can mimic virtually any disseminated fungal disease.

Round 4

User:

STAGE 4:

Seven days after returning home, weakness recurred without bulbar or respiratory symptoms. While additional immune-globulin infusions were being planned, a syncopal event occurred and the patient returned to the emergency department.

Second admission findings:
- The tongue ulcer persisted with worsening pain and masslike swelling of the left anterior tongue. CMV DNA had fallen to 75 IU/mL (good viral suppression on valganciclovir).
- Repeat tongue biopsy: edematous connective tissue containing spheroid and budding yeast forms. Grocott's methenamine silver and Fontana-Masson stains highlighted fungal elements; mucicarmine staining revealed a thick polysaccharide capsule characteristic of Cryptococcus species.
- Serum cryptococcal antigen (CrAg) lateral-flow assay: positive, titer >1:2560.
- Blood cultures grew creamy-white, smooth, mucoid colonies identified as Cryptococcus neoformans by MALDI-TOF; thick yeast with narrow-based budding and a prominent capsule.
- Because of the extremely high blood burden, a lumbar puncture was performed: CSF cultures grew C. neoformans, CSF cryptococcal antigen positive (titer >1:2560). Opening pressure was 24 cm of water, ranging 26-30 cm on subsequent measurements. A lumbar drain was placed to keep pressure <25 cm, later removed due to overdrainage/infection concerns, followed by daily therapeutic lumbar punctures and serial ophthalmologic exams.
Blurred vision and a mild frontal headache also developed. Despite treatment, blood cultures remained positive for C. neoformans for 2 weeks, and CSF Gram stain remained positive 1 month after starting treatment, reflecting an extremely high organism burden. After 1 month of treatment with persistent disease, ventricular fibrillation developed; the family had elected not to pursue resuscitation, and the patient died.

Resident:

Hello, Chief Resident here.

Key Findings: Persistent, masslike tongue lesion despite CMV clearance (75 IU/mL), high-titer Cryptococcus neoformans fungemia and neurocryptococcosis (serum/CSF CrAg >1:2560), refractory intracranial hypertension, and terminal ventricular fibrillation.

Differential Diagnoses:
1. Disseminated Cryptococcosis with Neurocryptococcosis: 85% – Unifies the refractory tongue lesion, fungemia, cryptococcal meningitis, severe ICP elevation, and terminal collapse in severe T-cell lymphopenia.
2. Cryptococcal IRIS: 10% – Immune restoration following MMF cessation and CMV treatment likely driven massive neuroinflammation and refractory ICP spikes.
3. Elevated ICP / Brainstem-Induced Terminal Arrhythmia: 5% – Autonomic dysregulation or Cushing's response triggering fatal VF secondary to extreme CNS pressure.

Key Clinical Takeaways:
1. Dual Pathogens: In profound T-cell lymphopenia (ALC 40/µL), identifying one pathogen (CMV) must not halt the search for concurrent opportunists.
2. Re-Biopsy Non-Healing Lesions: Persistent or evolving mucosal lesions despite target treatment mandate repeat biopsy to detect secondary invaders.
3. Screen Early: Serum Cryptococcal antigen testing should be part of the primary workup alongside Histoplasma testing in patients with severe iatrogenic immunosuppression presenting with fever, mucosal, or neurological signs.

Attending:

Hello Attending Consultant here

Critique: Accurate lock on dual OI and re-biopsy value, but underweights pre-mortem IRIS vs pure high-burden disease and omits why CrAg was never sent initially despite endemic risk + ALC 40. Terminal VF more likely ICP/autonomic than primary arrhythmia. No comment on missed induction antifungal intensity or flucytosine.

Top 3 DDx:
1. Disseminated C. neoformans (mucocutaneous + fungemia + meningitis) unmasked post-CMV
2. Cryptococcal IRIS driving refractory ICP
3. High-burden disease + secondary HLH/autonomic collapse

Specific points:
1. Admission CrAg + fungal blood cultures mandatory in any ALC <100 + mucosal lesion.
2. Induction: liposomal Ambisome + flucytosine; avoid monotherapy.
3. Serial OP q12–24 h; early EVD if drain fails.
4. Hold all IS agents; slow steroid wean only after sterility.
5. Retrospect ferritin/sIL-2R for concurrent HLH.
6. Autopsy correlation for dual-pathogen burden and IRIS histology.
7. Institutional lesson: multiplex OI panel (CrAg/Histo/CMV) before IVIG.

Expert:

Hello, Expert Clinician here.

Final unifying diagnosis: Disseminated Cryptococcus neoformans (mucocutaneous, fungemic, meningeal) with refractory intracranial hypertension — an unmasked co-infection in profound iatrogenic T-cell depletion (ALC 40/µL). Terminal VF likely reflected brainstem/autonomic compression from sustained ICP elevation.

Why alternatives fell away:
- Isolated CMV — cleared (75 IU/mL) while tongue lesion worsened; failure demanded re-biopsy, which yielded the second pathogen.
- IRIS — may have amplified CNS inflammation, but persistent positive cultures/gram stain at 4 weeks indicate uncontrolled organism burden, not sterile inflammation.
- Recurrent MG crisis — recurrent weakness was real but the fatal driver was cryptococcemia/CNS disease.

Key pivot: A non-healing tongue lesion despite successful treatment of the first isolate is itself a diagnostic test — re-biopsy converted closure into discovery.

Teaching pearl: In severe immunosuppression, pathogens travel in packs — one positive culture never excludes a second; re-biopsy any lesion that fails to heal on targeted therapy.

Top 15 Takeaways for Clinicians

  1. Biopsy the accessible lesion early. In iatrogenically immunosuppressed patients, an ulcerating mucosal lesion is the highest-yield diagnostic window — tissue with special stains and viral IHC beats empiricism and converts a broad differential into a treatable diagnosis.
  2. Know the "net state of immunosuppression." Combined glucocorticoid plus mycophenolate mofetil suppresses innate defenses and markedly impairs lymphocyte expansion, creating susceptibility to viral reactivation, invasive fungal disease, and mycobacterial infection.
  3. Absolute lymphopenia is a red flag. An ALC of 40/µL (reference 720–4100) signals profound T-cell depletion; every fever, mucosal ulcer, or pulmonary infiltrate in such a patient is an opportunistic infection until proven otherwise.
  4. Demand a unifying diagnosis. Destructive oral ulcers plus diarrhea, hypoxemia, cytopenias, and hepatitis in one patient is a single systemic process — resist anchoring on medication toxicity, a localized neoplasm, or a coexisting autoimmune flare.
  5. CMV reactivation is a multimodality masquerader. Disseminated CMV can simultaneously cause tissue-invasive oral ulcers, colitis, hepatitis, bone-marrow suppression, and pneumonitis — mimicking disseminated histoplasmosis or lymphoma.
  6. CMV serology distinguishes primary from reactivation. Positive CMV IgG with negative IgM and a quantitative CMV DNA of 6.27 million IU/mL indicates high-level reactivation of latent infection rather than primary acquisition.
  7. Ganciclovir myelotoxicity matters in cytopenic patients. Ganciclovir induction is standard for severe disseminated CMV, but its dose-limiting myelosuppression is a real concern in an already trilineage-cytopenic host — monitor counts and viral load closely.
  8. Transition to oral therapy when stable. Switch from intravenous ganciclovir to oral valganciclovir only after 2–3 weeks of therapy with a sustained viral decline, intact gastrointestinal absorption, and adequate renal function.
  9. CMV itself amplifies immunosuppression. Beyond direct tissue injury, CMV modulates antigen presentation and cytokine signaling and downregulates the scavenger receptors CD36 and SCARF1 on monocytes and macrophages — impairing clearance of pathogens such as Cryptococcus neoformans.
  10. Pathogens travel in packs. In profound immunosuppression, identifying one organism (CMV) must never halt the search for concurrent opportunists; a non-healing lesion despite treated viremia demands re-biopsy for a second invader.
  11. A non-healing lesion is itself a diagnostic test. The tongue ulcer that worsened despite a fall in CMV DNA (75 IU/mL) prompted re-biopsy, which revealed encapsulated budding yeast — cryptococcus — not refractory CMV.
  12. Screen for cryptococcus early. Serum cryptococcal antigen (lateral flow) plus fungal blood cultures should be part of the primary workup in any patient with severe iatrogenic immunosuppression, mucosal lesions, or neurologic symptoms — not a delayed afterthought.
  13. Treat cryptococcal meningitis in three phases. Induction with liposomal amphotericin B plus flucytosine (2 weeks), consolidation with fluconazole (8–10 weeks), then maintenance fluconazole for at least 12 months in immunocompromised hosts.
  14. Aggressively control intracranial pressure. Elevated ICP affects over half of cryptococcal meningitis cases and is a leading cause of death; use serial therapeutic lumbar punctures (target <25 cm water) and consider a lumbar drain/EVD — acetazolamide and mannitol are not recommended.
  15. High organism burden predicts death. Persistently positive blood cultures at 2 weeks and positive CSF Gram stain at 1 month reflect an overwhelming cryptococcal burden with a grim prognosis despite appropriate antifungal therapy and ICP management.